GSK Lays Out Five-Year Growth Strategy, Underpinned By Advair Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s five-year forecast includes the entry of Advair generics for the first time, but CEO Andrew Witty says pharma sales will nonetheless grow at low single-digits from 2016 to 2020.